APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Hypertension Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Pulmonary Hypertension Drug Market Analysis and Forecast 2026-2032

Report ID 174029990226 December 2025190 pages

Choose your research edition.

Industry ResearchPulmonary Hypertension Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Hypertension Drug Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Pulmonary Hypertension Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Hypertension Drug Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Hypertension Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Pulmonary Hypertension Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Pulmonary Hypertension Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Pulmonary Hypertension Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Pulmonary Hypertension Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Pulmonary Hypertension Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Pulmonary Hypertension Drug include Biolab Sanus Farmaceutica Ltda., Hanmi Pharmaceuticals, Co. Ltd., Ikaria Inc., Proreo Pharma AG, Vectura Group plc, Vicore Pharma AB, Bayer AG and Sanofi, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Pulmonary Hypertension Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Pulmonary Hypertension Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Pulmonary Hypertension Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pulmonary Hypertension Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pulmonary Hypertension Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Pulmonary Hypertension Drug sales, projected growth trends, production technology, application and end-user industry.

Pulmonary Hypertension Drug Segment by Company

Biolab Sanus Farmaceutica Ltda.

Hanmi Pharmaceuticals, Co. Ltd.

Ikaria Inc.

Proreo Pharma AG

Vectura Group plc

Vicore Pharma AB

Bayer AG

Sanofi

Pulmonary Hypertension Drug Segment by Type

IK-3001

Riociguat

Sildenafil Citrate IMD

SAR-407899

IK-7002

Others

Pulmonary Hypertension Drug Segment by Application

Clinic

Hospital

Others

Pulmonary Hypertension Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Hypertension Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Hypertension Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Hypertension Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Pulmonary Hypertension Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Pulmonary Hypertension Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pulmonary Hypertension Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pulmonary Hypertension Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. IK-3001 Major Manufacturers Table 3. Riociguat Major Manufacturers Table 4. Sildenafil Citrate IMD Major Manufacturers Table 5. SAR-407899 Major Manufacturers Table 6. IK-7002 Major Manufacturers Table 7. Others Major Manufacturers Table 8. Global Pulmonary Hypertension Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Clinic Major Manufacturers Table 10. Hospital Major Manufacturers Table 11. Others Major Manufacturers Table 12. Pulmonary Hypertension Drug Industry Trends Table 13. Pulmonary Hypertension Drug Industry Drivers Table 14. Pulmonary Hypertension Drug Industry Opportunities and Challenges Table 15. Pulmonary Hypertension Drug Industry Restraints Table 16. Global Pulmonary Hypertension Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Pulmonary Hypertension Drug Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Pulmonary Hypertension Drug Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Pulmonary Hypertension Drug Revenue Market Share by Region (2021-2026) Table 20. Global Pulmonary Hypertension Drug Revenue Market Share by Region (2027-2032) Table 21. Global Pulmonary Hypertension Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 22. Global Pulmonary Hypertension Drug Sales by Region (2021-2026) & (W Units) Table 23. Global Pulmonary Hypertension Drug Sales by Region (2027-2032) & (W Units) Table 24. Global Pulmonary Hypertension Drug Sales Market Share by Region (2021-2026) Table 25. Global Pulmonary Hypertension Drug Sales Market Share by Region (2027-2032) Table 26. Global Pulmonary Hypertension Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Pulmonary Hypertension Drug Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Pulmonary Hypertension Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Pulmonary Hypertension Drug Sales Market Share by Manufacturers (2021-2026) Table 30. Global Pulmonary Hypertension Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global Pulmonary Hypertension Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Pulmonary Hypertension Drug Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Pulmonary Hypertension Drug Manufacturers, Product Type & Application Table 34. Global Pulmonary Hypertension Drug Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Pulmonary Hypertension Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Pulmonary Hypertension Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Pulmonary Hypertension Drug Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Pulmonary Hypertension Drug Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Pulmonary Hypertension Drug Revenue Market Share by Type (2021-2026) Table 41. Global Pulmonary Hypertension Drug Revenue Market Share by Type (2027-2032) Table 42. Global Pulmonary Hypertension Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 43. Global Pulmonary Hypertension Drug Sales by Type (2021-2026) & (W Units) Table 44. Global Pulmonary Hypertension Drug Sales by Type (2027-2032) & (W Units) Table 45. Global Pulmonary Hypertension Drug Sales Market Share by Type (2021-2026) Table 46. Global Pulmonary Hypertension Drug Sales Market Share by Type (2027-2032) Table 47. Global Pulmonary Hypertension Drug Price by Type (2021-2026) & (US$/Unit) Table 48. Global Pulmonary Hypertension Drug Price by Type (2027-2032) & (US$/Unit) Table 49. Global Pulmonary Hypertension Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Pulmonary Hypertension Drug Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Pulmonary Hypertension Drug Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Pulmonary Hypertension Drug Revenue Market Share by Application (2021-2026) Table 53. Global Pulmonary Hypertension Drug Revenue Market Share by Application (2027-2032) Table 54. Global Pulmonary Hypertension Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 55. Global Pulmonary Hypertension Drug Sales by Application (2021-2026) & (W Units) Table 56. Global Pulmonary Hypertension Drug Sales by Application (2027-2032) & (W Units) Table 57. Global Pulmonary Hypertension Drug Sales Market Share by Application (2021-2026) Table 58. Global Pulmonary Hypertension Drug Sales Market Share by Application (2027-2032) Table 59. Global Pulmonary Hypertension Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Pulmonary Hypertension Drug Price by Application (2027-2032) & (US$/Unit) Table 61. Biolab Sanus Farmaceutica Ltda. Company Information Table 62. Biolab Sanus Farmaceutica Ltda. Business Overview Table 63. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Portfolio Table 65. Biolab Sanus Farmaceutica Ltda. Recent Development Table 66. Hanmi Pharmaceuticals, Co. Ltd. Company Information Table 67. Hanmi Pharmaceuticals, Co. Ltd. Business Overview Table 68. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product Portfolio Table 70. Hanmi Pharmaceuticals, Co. Ltd. Recent Development Table 71. Ikaria Inc. Company Information Table 72. Ikaria Inc. Business Overview Table 73. Ikaria Inc. Pulmonary Hypertension Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Ikaria Inc. Pulmonary Hypertension Drug Product Portfolio Table 75. Ikaria Inc. Recent Development Table 76. Proreo Pharma AG Company Information Table 77. Proreo Pharma AG Business Overview Table 78. Proreo Pharma AG Pulmonary Hypertension Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Proreo Pharma AG Pulmonary Hypertension Drug Product Portfolio Table 80. Proreo Pharma AG Recent Development Table 81. Vectura Group plc Company Information Table 82. Vectura Group plc Business Overview Table 83. Vectura Group plc Pulmonary Hypertension Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Vectura Group plc Pulmonary Hypertension Drug Product Portfolio Table 85. Vectura Group plc Recent Development Table 86. Vicore Pharma AB Company Information Table 87. Vicore Pharma AB Business Overview Table 88. Vicore Pharma AB Pulmonary Hypertension Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Vicore Pharma AB Pulmonary Hypertension Drug Product Portfolio Table 90. Vicore Pharma AB Recent Development Table 91. Bayer AG Company Information Table 92. Bayer AG Business Overview Table 93. Bayer AG Pulmonary Hypertension Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Bayer AG Pulmonary Hypertension Drug Product Portfolio Table 95. Bayer AG Recent Development Table 96. Sanofi Company Information Table 97. Sanofi Business Overview Table 98. Sanofi Pulmonary Hypertension Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Sanofi Pulmonary Hypertension Drug Product Portfolio Table 100. Sanofi Recent Development Table 101. North America Pulmonary Hypertension Drug Revenue by Type (2021-2026) & (US$ Million) Table 102. North America Pulmonary Hypertension Drug Revenue by Type (2027-2032) & (US$ Million) Table 103. North America Pulmonary Hypertension Drug Sales by Type (2021-2026) & (W Units) Table 104. North America Pulmonary Hypertension Drug Sales by Type (2027-2032) & (W Units) Table 105. North America Pulmonary Hypertension Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 106. North America Pulmonary Hypertension Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 107. North America Pulmonary Hypertension Drug Revenue by Application (2021-2026) & (US$ Million) Table 108. North America Pulmonary Hypertension Drug Revenue by Application (2027-2032) & (US$ Million) Table 109. North America Pulmonary Hypertension Drug Sales by Application (2021-2026) & (W Units) Table 110. North America Pulmonary Hypertension Drug Sales by Application (2027-2032) & (W Units) Table 111. North America Pulmonary Hypertension Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 112. North America Pulmonary Hypertension Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 113. North America Pulmonary Hypertension Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. North America Pulmonary Hypertension Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 115. North America Pulmonary Hypertension Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 116. North America Pulmonary Hypertension Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 117. North America Pulmonary Hypertension Drug Sales by Country (2021-2026) & (W Units) Table 118. North America Pulmonary Hypertension Drug Sales by Country (2027-2032) & (W Units) Table 119. North America Pulmonary Hypertension Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 120. North America Pulmonary Hypertension Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 121. United States Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 122. Canada Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 123. Mexico Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 124. Europe Pulmonary Hypertension Drug Revenue by Type (2021-2026) & (US$ Million) Table 125. Europe Pulmonary Hypertension Drug Revenue by Type (2027-2032) & (US$ Million) Table 126. Europe Pulmonary Hypertension Drug Sales by Type (2021-2026) & (W Units) Table 127. Europe Pulmonary Hypertension Drug Sales by Type (2027-2032) & (W Units) Table 128. Europe Pulmonary Hypertension Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 129. Europe Pulmonary Hypertension Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 130. Europe Pulmonary Hypertension Drug Revenue by Application (2021-2026) & (US$ Million) Table 131. Europe Pulmonary Hypertension Drug Revenue by Application (2027-2032) & (US$ Million) Table 132. Europe Pulmonary Hypertension Drug Sales by Application (2021-2026) & (W Units) Table 133. Europe Pulmonary Hypertension Drug Sales by Application (2027-2032) & (W Units) Table 134. Europe Pulmonary Hypertension Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 135. Europe Pulmonary Hypertension Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 136. Europe Pulmonary Hypertension Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. Europe Pulmonary Hypertension Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 138. Europe Pulmonary Hypertension Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 139. Europe Pulmonary Hypertension Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 140. Europe Pulmonary Hypertension Drug Sales by Country (2021-2026) & (W Units) Table 141. Europe Pulmonary Hypertension Drug Sales by Country (2027-2032) & (W Units) Table 142. Europe Pulmonary Hypertension Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 143. Europe Pulmonary Hypertension Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 144. Germany Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 145. France Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 146. U.K. Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 147. Italy Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 148. Russia Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 149. Spain Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 150. Netherlands Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 151. Switzerland Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 152. Sweden Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 153. Poland Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 154. China Pulmonary Hypertension Drug Revenue by Type (2021-2026) & (US$ Million) Table 155. China Pulmonary Hypertension Drug Revenue by Type (2027-2032) & (US$ Million) Table 156. China Pulmonary Hypertension Drug Sales by Type (2021-2026) & (W Units) Table 157. China Pulmonary Hypertension Drug Sales by Type (2027-2032) & (W Units) Table 158. China Pulmonary Hypertension Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 159. China Pulmonary Hypertension Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 160. China Pulmonary Hypertension Drug Revenue by Application (2021-2026) & (US$ Million) Table 161. China Pulmonary Hypertension Drug Revenue by Application (2027-2032) & (US$ Million) Table 162. China Pulmonary Hypertension Drug Sales by Application (2021-2026) & (W Units) Table 163. China Pulmonary Hypertension Drug Sales by Application (2027-2032) & (W Units) Table 164. China Pulmonary Hypertension Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 165. China Pulmonary Hypertension Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 166. Asia Pulmonary Hypertension Drug Revenue by Type (2021-2026) & (US$ Million) Table 167. Asia Pulmonary Hypertension Drug Revenue by Type (2027-2032) & (US$ Million) Table 168. Asia Pulmonary Hypertension Drug Sales by Type (2021-2026) & (W Units) Table 169. Asia Pulmonary Hypertension Drug Sales by Type (2027-2032) & (W Units) Table 170. Asia Pulmonary Hypertension Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 171. Asia Pulmonary Hypertension Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 172. Asia Pulmonary Hypertension Drug Revenue by Application (2021-2026) & (US$ Million) Table 173. Asia Pulmonary Hypertension Drug Revenue by Application (2027-2032) & (US$ Million) Table 174. Asia Pulmonary Hypertension Drug Sales by Application (2021-2026) & (W Units) Table 175. Asia Pulmonary Hypertension Drug Sales by Application (2027-2032) & (W Units) Table 176. Asia Pulmonary Hypertension Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 177. Asia Pulmonary Hypertension Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 178. Asia Pulmonary Hypertension Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 179. Asia Pulmonary Hypertension Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 180. Asia Pulmonary Hypertension Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 181. Asia Pulmonary Hypertension Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 182. Asia Pulmonary Hypertension Drug Sales by Country (2021-2026) & (W Units) Table 183. Asia Pulmonary Hypertension Drug Sales by Country (2027-2032) & (W Units) Table 184. Asia Pulmonary Hypertension Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 185. Asia Pulmonary Hypertension Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 186. Japan Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 187. South Korea Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 188. India Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 189. Australia Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 190. Taiwan Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 191. Southeast Asia Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 192. SAMEA Pulmonary Hypertension Drug Revenue by Type (2021-2026) & (US$ Million) Table 193. SAMEA Pulmonary Hypertension Drug Revenue by Type (2027-2032) & (US$ Million) Table 194. SAMEA Pulmonary Hypertension Drug Sales by Type (2021-2026) & (W Units) Table 195. SAMEA Pulmonary Hypertension Drug Sales by Type (2027-2032) & (W Units) Table 196. SAMEA Pulmonary Hypertension Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 197. SAMEA Pulmonary Hypertension Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 198. SAMEA Pulmonary Hypertension Drug Revenue by Application (2021-2026) & (US$ Million) Table 199. SAMEA Pulmonary Hypertension Drug Revenue by Application (2027-2032) & (US$ Million) Table 200. SAMEA Pulmonary Hypertension Drug Sales by Application (2021-2026) & (W Units) Table 201. SAMEA Pulmonary Hypertension Drug Sales by Application (2027-2032) & (W Units) Table 202. SAMEA Pulmonary Hypertension Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 203. SAMEA Pulmonary Hypertension Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 204. SAMEA Pulmonary Hypertension Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 205. SAMEA Pulmonary Hypertension Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 206. SAMEA Pulmonary Hypertension Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 207. SAMEA Pulmonary Hypertension Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 208. SAMEA Pulmonary Hypertension Drug Sales by Country (2021-2026) & (W Units) Table 209. SAMEA Pulmonary Hypertension Drug Sales by Country (2027-2032) & (W Units) Table 210. SAMEA Pulmonary Hypertension Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 211. SAMEA Pulmonary Hypertension Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 212. Brazil Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 213. Argentina Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 214. Chile Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 215. Colombia Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 216. Peru Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 217. Saudi Arabia Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 218. Israel Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 219. UAE Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 220. Turkey Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 221. Iran Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 222. Egypt Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 223. Key Raw Materials Table 224. Raw Materials Key Suppliers Table 225. Pulmonary Hypertension Drug Distributors List Table 226. Pulmonary Hypertension Drug Customers List Table 227. Research Programs/Design for This Report Table 228. Authors List of This Report Table 229. Secondary Sources Table 230. Primary Sources List of Figures Figure 1. Pulmonary Hypertension Drug Image Figure 2. Global Pulmonary Hypertension Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Hypertension Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. IK-3001 Image Figure 5. Riociguat Image Figure 6. Sildenafil Citrate IMD Image Figure 7. SAR-407899 Image Figure 8. IK-7002 Image Figure 9. Others Image Figure 10. Global Pulmonary Hypertension Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Pulmonary Hypertension Drug Market Size Share 2021 VS 2025 VS 2032 Figure 12. Clinic Image Figure 13. Hospital Image Figure 14. Others Image Figure 15. Global Pulmonary Hypertension Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Pulmonary Hypertension Drug Revenue (2021-2032) & (US$ Million) Figure 17. Global Pulmonary Hypertension Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Pulmonary Hypertension Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Pulmonary Hypertension Drug Revenue Market Share by Region (2021-2032) Figure 20. Global Pulmonary Hypertension Drug Sales (2021-2032) & (W Units) Figure 21. Global Pulmonary Hypertension Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 22. Global Pulmonary Hypertension Drug Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Pulmonary Hypertension Drug Sales YoY (2021-2032) & (W Units) Figure 24. Europe Pulmonary Hypertension Drug Sales YoY (2021-2032) & (W Units) Figure 25. China Pulmonary Hypertension Drug Sales YoY (2021-2032) & (W Units) Figure 26. Asia (Excluding China) Pulmonary Hypertension Drug Sales YoY (2021-2032) & (W Units) Figure 27. South America, Middle East and Africa Pulmonary Hypertension Drug Sales YoY (2021-2032) & (W Units) Figure 28. Global Pulmonary Hypertension Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Pulmonary Hypertension Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Pulmonary Hypertension Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Pulmonary Hypertension Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Pulmonary Hypertension Drug Revenue Market Share by Type (2021-2032) Figure 34. Global Pulmonary Hypertension Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 35. Global Pulmonary Hypertension Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Pulmonary Hypertension Drug Sales Market Share by Type (2021-2032) Figure 37. Global Pulmonary Hypertension Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Pulmonary Hypertension Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Pulmonary Hypertension Drug Revenue Market Share by Application (2021-2032) Figure 40. Global Pulmonary Hypertension Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 41. Global Pulmonary Hypertension Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Pulmonary Hypertension Drug Sales Market Share by Application (2021-2032) Figure 43. North America Pulmonary Hypertension Drug Revenue Share by Type (2021-2032) Figure 44. North America Pulmonary Hypertension Drug Sales Share by Type (2021-2032) Figure 45. North America Pulmonary Hypertension Drug Revenue Share by Application (2021-2032) Figure 46. North America Pulmonary Hypertension Drug Sales Share by Application (2021-2032) Figure 47. North America Pulmonary Hypertension Drug Revenue Share by Country (2021-2032) Figure 48. North America Pulmonary Hypertension Drug Sales Share by Country (2021-2032) Figure 49. Europe Pulmonary Hypertension Drug Revenue Share by Type (2021-2032) Figure 50. Europe Pulmonary Hypertension Drug Sales Share by Type (2021-2032) Figure 51. Europe Pulmonary Hypertension Drug Revenue Share by Application (2021-2032) Figure 52. Europe Pulmonary Hypertension Drug Sales Share by Application (2021-2032) Figure 53. Europe Pulmonary Hypertension Drug Revenue Share by Country (2021-2032) Figure 54. Europe Pulmonary Hypertension Drug Sales Share by Country (2021-2032) Figure 55. China Pulmonary Hypertension Drug Revenue Share by Type (2021-2032) Figure 56. China Pulmonary Hypertension Drug Sales Share by Type (2021-2032) Figure 57. China Pulmonary Hypertension Drug Revenue Share by Application (2021-2032) Figure 58. China Pulmonary Hypertension Drug Sales Share by Application (2021-2032) Figure 59. Asia Pulmonary Hypertension Drug Revenue Share by Type (2021-2032) Figure 60. Asia Pulmonary Hypertension Drug Sales Share by Type (2021-2032) Figure 61. Asia Pulmonary Hypertension Drug Revenue Share by Application (2021-2032) Figure 62. Asia Pulmonary Hypertension Drug Sales Share by Application (2021-2032) Figure 63. Asia Pulmonary Hypertension Drug Revenue Share by Country (2021-2032) Figure 64. Asia Pulmonary Hypertension Drug Sales Share by Country (2021-2032) Figure 65. SAMEA Pulmonary Hypertension Drug Revenue Share by Type (2021-2032) Figure 66. SAMEA Pulmonary Hypertension Drug Sales Share by Type (2021-2032) Figure 67. SAMEA Pulmonary Hypertension Drug Revenue Share by Application (2021-2032) Figure 68. SAMEA Pulmonary Hypertension Drug Sales Share by Application (2021-2032) Figure 69. SAMEA Pulmonary Hypertension Drug Revenue Share by Country (2021-2032) Figure 70. SAMEA Pulmonary Hypertension Drug Sales Share by Country (2021-2032) Figure 71. Pulmonary Hypertension Drug Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Pulmonary Hypertension Drug Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • IK-3001
  • Riociguat
  • Sildenafil Citrate IMD
  • SAR-407899
  • IK-7002
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Biolab Sanus Farmaceutica Ltda.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Ikaria Inc.
  • Proreo Pharma AG
  • Vectura Group plc
  • Vicore Pharma AB
  • Bayer AG
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pulmonary Hypertension Drug Market by Type
  3. 1.2.1 Global Pulmonary Hypertension Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 IK-3001
  5. 1.2.3 Riociguat
  6. 1.2.4 Sildenafil Citrate IMD
  7. 1.2.5 SAR-407899
  8. 1.2.6 IK-7002
  9. 1.2.7 Others
  10. 1.3 Pulmonary Hypertension Drug Market by Application
  11. 1.3.1 Global Pulmonary Hypertension Drug Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Clinic
  13. 1.3.3 Hospital
  14. 1.3.4 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Pulmonary Hypertension Drug Market Dynamics
  1. 2.1 Pulmonary Hypertension Drug Industry Trends
  2. 2.2 Pulmonary Hypertension Drug Industry Drivers
  3. 2.3 Pulmonary Hypertension Drug Industry Opportunities and Challenges
  4. 2.4 Pulmonary Hypertension Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Pulmonary Hypertension Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Pulmonary Hypertension Drug Revenue by Region
  3. 3.2.1 Global Pulmonary Hypertension Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pulmonary Hypertension Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Pulmonary Hypertension Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Pulmonary Hypertension Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Pulmonary Hypertension Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Pulmonary Hypertension Drug Sales by Region
  9. 3.4.1 Global Pulmonary Hypertension Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Pulmonary Hypertension Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Pulmonary Hypertension Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Pulmonary Hypertension Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Pulmonary Hypertension Drug Revenue by Manufacturers
  2. 4.1.1 Global Pulmonary Hypertension Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Pulmonary Hypertension Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Pulmonary Hypertension Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pulmonary Hypertension Drug Sales by Manufacturers
  6. 4.2.1 Global Pulmonary Hypertension Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Pulmonary Hypertension Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Pulmonary Hypertension Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Pulmonary Hypertension Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Pulmonary Hypertension Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Pulmonary Hypertension Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Pulmonary Hypertension Drug Manufacturers, Product Type & Application
  13. 4.7 Global Pulmonary Hypertension Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Pulmonary Hypertension Drug Market CR5 and HHI
  16. 4.8.2 2025 Pulmonary Hypertension Drug Tier 1, Tier 2, and Tier 3
5 Pulmonary Hypertension Drug Market by Type
  1. 5.1 Global Pulmonary Hypertension Drug Revenue by Type
  2. 5.1.1 Global Pulmonary Hypertension Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Pulmonary Hypertension Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Pulmonary Hypertension Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Pulmonary Hypertension Drug Sales by Type
  6. 5.2.1 Global Pulmonary Hypertension Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pulmonary Hypertension Drug Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Pulmonary Hypertension Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Pulmonary Hypertension Drug Price by Type
6 Pulmonary Hypertension Drug Market by Application
  1. 6.1 Global Pulmonary Hypertension Drug Revenue by Application
  2. 6.1.1 Global Pulmonary Hypertension Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Pulmonary Hypertension Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Pulmonary Hypertension Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Pulmonary Hypertension Drug Sales by Application
  6. 6.2.1 Global Pulmonary Hypertension Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Pulmonary Hypertension Drug Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Pulmonary Hypertension Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Pulmonary Hypertension Drug Price by Application
7 Company Profiles
  1. 7.1 Biolab Sanus Farmaceutica Ltda.
  2. 7.1.1 Biolab Sanus Farmaceutica Ltda. Company Information
  3. 7.1.2 Biolab Sanus Farmaceutica Ltda. Business Overview
  4. 7.1.3 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Portfolio
  6. 7.1.5 Biolab Sanus Farmaceutica Ltda. Recent Developments
  7. 7.2 Hanmi Pharmaceuticals, Co. Ltd.
  8. 7.2.1 Hanmi Pharmaceuticals, Co. Ltd. Company Information
  9. 7.2.2 Hanmi Pharmaceuticals, Co. Ltd. Business Overview
  10. 7.2.3 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product Portfolio
  12. 7.2.5 Hanmi Pharmaceuticals, Co. Ltd. Recent Developments
  13. 7.3 Ikaria Inc.
  14. 7.3.1 Ikaria Inc. Company Information
  15. 7.3.2 Ikaria Inc. Business Overview
  16. 7.3.3 Ikaria Inc. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Ikaria Inc. Pulmonary Hypertension Drug Product Portfolio
  18. 7.3.5 Ikaria Inc. Recent Developments
  19. 7.4 Proreo Pharma AG
  20. 7.4.1 Proreo Pharma AG Company Information
  21. 7.4.2 Proreo Pharma AG Business Overview
  22. 7.4.3 Proreo Pharma AG Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Proreo Pharma AG Pulmonary Hypertension Drug Product Portfolio
  24. 7.4.5 Proreo Pharma AG Recent Developments
  25. 7.5 Vectura Group plc
  26. 7.5.1 Vectura Group plc Company Information
  27. 7.5.2 Vectura Group plc Business Overview
  28. 7.5.3 Vectura Group plc Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Vectura Group plc Pulmonary Hypertension Drug Product Portfolio
  30. 7.5.5 Vectura Group plc Recent Developments
  31. 7.6 Vicore Pharma AB
  32. 7.6.1 Vicore Pharma AB Company Information
  33. 7.6.2 Vicore Pharma AB Business Overview
  34. 7.6.3 Vicore Pharma AB Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Vicore Pharma AB Pulmonary Hypertension Drug Product Portfolio
  36. 7.6.5 Vicore Pharma AB Recent Developments
  37. 7.7 Bayer AG
  38. 7.7.1 Bayer AG Company Information
  39. 7.7.2 Bayer AG Business Overview
  40. 7.7.3 Bayer AG Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Bayer AG Pulmonary Hypertension Drug Product Portfolio
  42. 7.7.5 Bayer AG Recent Developments
  43. 7.8 Sanofi
  44. 7.8.1 Sanofi Company Information
  45. 7.8.2 Sanofi Business Overview
  46. 7.8.3 Sanofi Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Sanofi Pulmonary Hypertension Drug Product Portfolio
  48. 7.8.5 Sanofi Recent Developments
8 North America
  1. 8.1 North America Pulmonary Hypertension Drug Market Size by Type
  2. 8.1.1 North America Pulmonary Hypertension Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Pulmonary Hypertension Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Pulmonary Hypertension Drug Price by Type (2021-2032)
  5. 8.2 North America Pulmonary Hypertension Drug Market Size by Application
  6. 8.2.1 North America Pulmonary Hypertension Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Pulmonary Hypertension Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Pulmonary Hypertension Drug Price by Application (2021-2032)
  9. 8.3 North America Pulmonary Hypertension Drug Market Size by Country
  10. 8.3.1 North America Pulmonary Hypertension Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Pulmonary Hypertension Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Pulmonary Hypertension Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Pulmonary Hypertension Drug Market Size by Type
  2. 9.1.1 Europe Pulmonary Hypertension Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Pulmonary Hypertension Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Pulmonary Hypertension Drug Price by Type (2021-2032)
  5. 9.2 Europe Pulmonary Hypertension Drug Market Size by Application
  6. 9.2.1 Europe Pulmonary Hypertension Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Pulmonary Hypertension Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Pulmonary Hypertension Drug Price by Application (2021-2032)
  9. 9.3 Europe Pulmonary Hypertension Drug Market Size by Country
  10. 9.3.1 Europe Pulmonary Hypertension Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Pulmonary Hypertension Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Pulmonary Hypertension Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Pulmonary Hypertension Drug Market Size by Type
  2. 10.1.1 China Pulmonary Hypertension Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Pulmonary Hypertension Drug Sales by Type (2021-2032)
  4. 10.1.3 China Pulmonary Hypertension Drug Price by Type (2021-2032)
  5. 10.2 China Pulmonary Hypertension Drug Market Size by Application
  6. 10.2.1 China Pulmonary Hypertension Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Pulmonary Hypertension Drug Sales by Application (2021-2032)
  8. 10.2.3 China Pulmonary Hypertension Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pulmonary Hypertension Drug Market Size by Type
  2. 11.1.1 Asia Pulmonary Hypertension Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Pulmonary Hypertension Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Pulmonary Hypertension Drug Price by Type (2021-2032)
  5. 11.2 Asia Pulmonary Hypertension Drug Market Size by Application
  6. 11.2.1 Asia Pulmonary Hypertension Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Pulmonary Hypertension Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Pulmonary Hypertension Drug Price by Application (2021-2032)
  9. 11.3 Asia Pulmonary Hypertension Drug Market Size by Country
  10. 11.3.1 Asia Pulmonary Hypertension Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Pulmonary Hypertension Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Pulmonary Hypertension Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pulmonary Hypertension Drug Market Size by Type
  2. 12.1.1 SAMEA Pulmonary Hypertension Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Pulmonary Hypertension Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Pulmonary Hypertension Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Pulmonary Hypertension Drug Market Size by Application
  6. 12.2.1 SAMEA Pulmonary Hypertension Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Pulmonary Hypertension Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Pulmonary Hypertension Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Pulmonary Hypertension Drug Market Size by Country
  10. 12.3.1 SAMEA Pulmonary Hypertension Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Pulmonary Hypertension Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Pulmonary Hypertension Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Pulmonary Hypertension Drug Value Chain Analysis
  2. 13.1.1 Pulmonary Hypertension Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Pulmonary Hypertension Drug Production Mode & Process
  6. 13.2 Pulmonary Hypertension Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Pulmonary Hypertension Drug Distributors
  9. 13.2.3 Pulmonary Hypertension Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst